Omada Health (OMDA) announced new study results demonstrating that Omada members in its GLP-1 Care Track lost, on average, 1.8 times more total weight and reduced their body fat percentage twice as much as the comparison group. The Omada members also saw an increase in muscle mass percentage and improvements in other well-being measures. These findings suggest that Omada’s program may optimize the weight loss results of GLP-1s, mitigating a key risk of muscle loss associated with GLP-1s. “Too often, patients are prescribed GLP-1s and left on their own with vague advice to make lifestyle changes to meet their goals and improve their health,” said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. “Omada is designed to not only support members through their whole GLP-1 treatment journey, but to also increase the quality of the weight loss. Instead of only changing the number on the scale, the Omada program has demonstrated that it can change what that number is made of: more fat loss, preserved muscle, and better daily functioning.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health initiated with an Outperform at Citizens
- Omada Health price target lowered to $15 from $20 at Evercore ISI
- Omada Health price target lowered to $26 from $32 at JPMorgan
- Omada Health Earnings Call Highlights Profitable Growth
- Omada Health: Profitability Inflection, Double-Digit Growth Outlook, and Undervalued Upside Support Buy Rating
